Diabetes management programs can be delivered digitally or in a traditional in-person setting, but there are benefits and drawbacks to each, explained Neal Kaufman, MD, founder and chief medical officer of Canary Health.
Diabetes management programs can be delivered digitally or in a traditional in-person setting, but there are benefits and drawbacks to each, explained Neal Kaufman, MD, founder and chief medical officer of Canary Health.
Transcript (slightly modified)
What are the advantages of digital delivery of a chronic disease management program, compared with an in-person program?
I think they’re both very important. They’re both excellent ways of bringing research-proven approaches to help people self-manage their conditions. Digital has certain advantages over in-person, and in-person has advantages over digital.
Digital is ubiquitous, 24/7, the person doesn’t need to get in their car to get to the appointment, they can access it from the privacy of their home, they can come on for 5 or 10 minutes if that’s all they have that day, or they can spend an hour or longer if need be. It identifies and helps people who don’t like to join groups. Many people are not happy with that approach; they want to be anonymous in their conversations.
In-person is in-person, and it allows you to have a more intimate relationship with individuals who come to your group. It has benefits where individuals are able to share and have that direct social support. Digital provides indirect social support, and depending on the individual, some approaches work better than others.
In-person has a challenge, in that you have to get people to show up at the same time, at the same place, an hour a week or more depending on the program, and that can have some significant logistics challenges.
So, I actually believe that the future will have combined approaches where individuals will be given the choice between a digital delivery of that program, in this case a diabetes prevention program or a chronic disease self-management program, and also in-person delivery of those same programs.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More